Arvinas, Inc. (ARVN)

$44.49

-0.31 (-0.69%)
Rating:
Recommendation:
-
Symbol ARVN
Price $44.49
Beta 2.060
Volume Avg. 0.39M
Market Cap 2.367B
Shares () -
52 Week Range 34.9-97.33
1y Target Est -
DCF Unlevered ARVN DCF ->
DCF Levered ARVN LDCF ->
ROE -31.16% Strong Sell
ROA -16.57% Sell
Operating Margin -
Debt / Equity 109.81% Buy
P/E -
P/B 3.53 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest ARVN news


Dr. John Houston
Healthcare
Biotechnology
NASDAQ Global Select

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.